Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Corcept Therapeutics (CORT) over the last 13 years, with Sep 2025 value amounting to $105.4 million.

  • Corcept Therapeutics' Shares Outstanding (Weighted Average) rose 0.84% to $105.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.4 million, marking a year-over-year increase of 0.84%. This contributed to the annual value of $104.8 million for FY2024, which is 1.64% up from last year.
  • Corcept Therapeutics' Shares Outstanding (Weighted Average) amounted to $105.4 million in Q3 2025, which was down 0.63% from $106.0 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Shares Outstanding (Weighted Average) peaked at $117.3 million during Q1 2021, and registered a low of $101.6 million during Q2 2023.
  • For the 3-year period, Corcept Therapeutics' Shares Outstanding (Weighted Average) averaged around $104.4 million, with its median value being $104.5 million (2024).
  • Per our database at Business Quant, Corcept Therapeutics' Shares Outstanding (Weighted Average) decreased by 9.67% in 2022 and then increased by 2.49% in 2024.
  • Quarterly analysis of 5 years shows Corcept Therapeutics' Shares Outstanding (Weighted Average) stood at $115.5 million in 2021, then declined by 6.76% to $107.6 million in 2022, then declined by 4.24% to $103.1 million in 2023, then climbed by 1.64% to $104.8 million in 2024, then grew by 0.84% to $105.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $105.4 million in Q3 2025, compared to $106.0 million in Q2 2025 and $105.5 million in Q1 2025.